Martin Kimmich

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto et al. · The Lancet Oncology · 2019 · 613 citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)

Wilfried Eberhardt, Christoph Pöttgen, Thomas Gauler et al. · Journal of Clinical Oncology · 2015 · 365 citations

Medicine, Oncology, Surgery +16

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Markus Joerger, Joachim von Pawel, Stefanie Kraff et al. · Annals of Oncology · 2016 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients

Giorgio V. Scagliotti, Denis Moro‐Sibilot, Jens Kollmeier et al. · Journal of Thoracic Oncology · 2019 · 78 citations

Pharmacy, Oncology, Pharmacology +12

Phase II Trial of a Trimodality Regimen for Stage III Non–Small-Cell Lung Cancer Using Chemotherapy As Induction Treatment With Concurrent Hyperfractionated Chemoradiation With Carboplatin and Paclitaxel Followed by Subsequent Resection: A Single-Center Study

Godehard Friedel, Wilfried Budach, Juergen Dippon et al. · Journal of Clinical Oncology · 2010 · 77 citations · Full text

Medicine, Oncology, Surgery +17